Trade Amgen - AMGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.26 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02354% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001318% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 307.88 |
| Open | 310.25 |
| 1-Year Change | 10.72% |
| Day's Range | 310.25 - 311.82 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 28, 2025 | 307.88 | 1.74 | 0.57% | 306.14 | 308.43 | 303.12 |
| Feb 27, 2025 | 305.31 | 0.81 | 0.27% | 304.50 | 310.82 | 301.84 |
| Feb 26, 2025 | 306.29 | -5.93 | -1.90% | 312.22 | 313.04 | 305.34 |
| Feb 25, 2025 | 315.55 | 5.91 | 1.91% | 309.64 | 318.09 | 309.64 |
| Feb 24, 2025 | 309.58 | 6.05 | 1.99% | 303.53 | 312.97 | 303.53 |
| Feb 21, 2025 | 302.69 | 4.23 | 1.42% | 298.46 | 305.13 | 295.91 |
| Feb 20, 2025 | 297.88 | 3.71 | 1.26% | 294.17 | 298.05 | 292.71 |
| Feb 19, 2025 | 294.04 | 2.78 | 0.95% | 291.26 | 295.77 | 291.22 |
| Feb 18, 2025 | 292.61 | 1.91 | 0.66% | 290.70 | 293.12 | 288.22 |
| Feb 14, 2025 | 290.43 | -1.95 | -0.67% | 292.38 | 294.76 | 290.32 |
| Feb 13, 2025 | 296.78 | -0.11 | -0.04% | 296.89 | 297.53 | 292.43 |
| Feb 12, 2025 | 295.15 | 1.69 | 0.58% | 293.46 | 296.11 | 291.84 |
| Feb 11, 2025 | 296.27 | 7.60 | 2.63% | 288.67 | 297.84 | 287.23 |
| Feb 10, 2025 | 294.69 | -0.36 | -0.12% | 295.05 | 295.05 | 290.12 |
| Feb 7, 2025 | 293.43 | -4.84 | -1.62% | 298.27 | 298.49 | 292.48 |
| Feb 6, 2025 | 297.70 | -10.95 | -3.55% | 308.65 | 308.79 | 294.95 |
| Feb 5, 2025 | 307.62 | 17.72 | 6.11% | 289.90 | 308.14 | 288.05 |
| Feb 4, 2025 | 288.95 | 3.70 | 1.30% | 285.25 | 290.14 | 283.22 |
| Feb 3, 2025 | 288.66 | 2.09 | 0.73% | 286.57 | 289.47 | 282.56 |
| Jan 31, 2025 | 285.35 | 3.58 | 1.27% | 281.77 | 286.54 | 281.77 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Amgen Company profile
About Amgen, Inc.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Amgen, Inc. revenues increased 2% to $25.98B. Net income decreased 19% to $5.89B. Revenues reflect Other revenues segment increase of 42% to $1.68B, Prolia segment increase of 18% to $3.25B, ROW segment increase of 12% to $7.01B, Other revenues segment increase of 42% to $1.68B. Net income was offset by Research and development increase of 15% to $4.82B (expense), Other increase of 3% to $194M (expense).
Equity composition
Common Stock $.0001 Par, 4/11, 2.75B auth., 929,730,507 issd. Insiders own 0.12% . IPO 5/87, 2M shares @ $34 by Paine Webber. 9/91, 3-for-1 split; 11/99, 3/99, 8/95, 7/90, 2-for-1 splits. 7/02, Company acquired Immunex Corp. @ $4.50/share and 0.44 shs. (242,916,735 shs. issd.).
| Industry: | Pharmaceuticals (NEC) |
One Amgen Center Drive
THOUSAND OAKS
CALIFORNIA 91320-1799
US
News
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com